Carbogen gas and radiotherapy outcomes in prostate cancer.

about

Formononetin induces apoptosis in PC-3 prostate cancer cells through enhancing the Bax/Bcl-2 ratios and regulating the p38/Akt pathway.

P2860

Q39012041-6BAC9123-03C0-4881-8867-E29EB51E5F44

P2860

Carbogen gas and radiotherapy outcomes in prostate cancer.

Item

http://www.wikidata.org/entity/Q38078362

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Carbogen gas and radiotherapy outcomes in prostate cancer.

@en

type

Item

label

Carbogen gas and radiotherapy outcomes in prostate cancer.

@en

prefLabel

Carbogen gas and radiotherapy outcomes in prostate cancer.

@en

P1476

Carbogen gas and radiotherapy outcomes in prostate cancer.

@en

P2093

Kent Yip

http://www.w3.org/2001/XMLSchema#string

Roberto Alonzi

http://www.w3.org/2001/XMLSchema#string

P2860

Radiosensitization and stromal imaging response correlates for the HIF-1 inhibitor PX-478 given with or without chemotherapy in pancreatic cancer

The prognostic value of the hypoxia markers CA IX and GLUT 1 and the cytokines VEGF and IL 6 in head and neck squamous cell carcinoma treated by radiotherapy +/- chemotherapy

Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase

Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects

Exploiting tumour hypoxia in cancer treatment

Tirapazamine, cisplatin, and radiation versus cisplatin and radiation for advanced squamous cell carcinoma of the head and neck (TROG 02.02, HeadSTART): a phase III trial of the Trans-Tasman Radiation Oncology Group

Fas antigen/CD-95 upregulation and activation during castration-induced regression of the rat ventral prostate gland

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial

P304

25-34

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/1756287212452195

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2013-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23372608

http://www.w3.org/2001/XMLSchema#string

P932

3547529

http://www.w3.org/2001/XMLSchema#string

Carbogen gas and radiotherapy outcomes in prostate cancer.

about

P2860

P2860

Carbogen gas and radiotherapy outcomes in prostate cancer.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P932